Prostate cancer is the most common cancer in males in the UK, with over 48,000 new prostate cancer cases diagnosed in the UK each year. Although about half of prostate cancer patients will die with the cancer rather than of it, prostate cancer is still the second leading cause of cancer mortality in males in the UK. It is currently difficult to distinguish between latent and aggressive cancers, and once prostate cancer spreads, it is incurable. Therefore, it is important to identify factors that influence both prostate cancer progression and the therapeutic response, and which could be used to develop biomarkers for tumour behaviour and potential targets for novel therapies.
Image credit: Prostate cancer cells. Anne Weston, Francis Crick Institute. CC BY-NC